Trispecific and trivalent binding proteins represent a breakthrough in the battle against HIV infection. These specialized proteins are engineered with four polypeptide chains forming three antigen binding sites, enabling precise targeting of HIV target proteins. Addressing the formidable challenges of HIV treatment, including the virus's high mutation rate and the persistence of viral reservoirs, these binding proteins offer a potential solution to breakthrough infections. Their unique structure incorporates dual variable domains in one pair of polypeptides and a single variable domain in the other, enhancing their ability to recognize and neutralize HIV. By engaging HIV-1 envelope proteins and human T cell antigens, these proteins activate viral reservoirs and host T cells, effectively redirecting T cells to combat HIV-1 latency. This technology holds the promise of broadening the scope of neutralizing antibodies, potentially revolutionizing treatment options for HIV/AIDS.